MacroGenics, Inc. is a clinical-stage biopharmaceutical company headquartered in Rockville, Maryland, that develops antibody-based therapies aimed at treating cancer. Its approach relies on proprietary platforms such as the DART and TRIDENT bispecific technologies along with topoisomerase I inhibitor-based antibody-drug conjugate programs.
Key candidates in the pipeline include lorigerlimab, a PD-1 x CTLA-4 bispecific DART molecule, and MGC026, a B7-H3-directed ADC. The company also maintains partnerships that provide milestone and royalty opportunities, including work with Gilead Sciences, Sanofi on TZIELD, and Incyte on ZYNYZ. Clinical readouts remain central to how investors assess the shares.
Shares of MGNX have declined about 44% in the last 30 days, moving from a closing price near $3.59 in late October to roughly $2.00 in the most recent session. A single-day drop of approximately 38% on October 23, 2026, on elevated volume stood out as the sharpest move.
The quarterly picture shows an even larger decline. Three months earlier the stock traded near $4.07, so the shares have lost roughly 51% of their value over that span. After reaching the low-$4 range in August and early September, the stock entered a sustained pullback that intensified after the October data releases.
The standout event was the October 23, 2026, release of positive interim Phase 1 results for MGC026 at the ESMO 2026 Congress. The data indicated a 27% best overall response rate in heavily pretreated SCCHN patients, along with a manageable safety profile and no reported cases of interstitial lung disease or ocular toxicity.
Even with the encouraging framing, the stock fell about 38% that day. While company disclosures did not fully detail the driver, the reaction fits a pattern seen with clinical-stage biotechs where investors focus on durability, competition, and potential dilution. A broader risk-off tone across cash-burning development-stage names added pressure. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Later in October the company released positive interim Phase 2 LINNET results for lorigerlimab in advanced clear cell gynecologic cancer, showing a confirmed objective response rate of 25% and a disease control rate of 44%. Third-quarter results and the addition of two new independent directors in mid-November followed, yet none of these updates halted the downward trend.
Over the quarter the stock moved from the $4 range down toward $2, representing a decline of roughly 51%. Shares peaked in the low-$4s in early September before a steady descent that reflected caution ahead of the ESMO presentations and wider weakness among small-cap biotechs.
Corporate restructuring also featured in the period. MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million and shifted to a fully outsourced model with a smaller workforce. This left the company with pro forma cash of about $327 million and an extended runway through 2028. While the improved financial position added flexibility, the clinical data-driven repricing remained the dominant influence on performance.
Looking forward, attention will likely center on further clinical updates. The company expects to finish enrolling clear cell gynecologic cancer patients at the lower lorigerlimab dose by the end of 2026, with updated results expected in the first half of 2027. Additional data from the MGC026 program and progress on MGC030, which dosed its first patient in October, will also draw scrutiny.
Macroeconomic elements such as interest-rate expectations and financing conditions for development-stage biotechs continue to shape sentiment. Competitive shifts in the ADC and bispecific spaces, along with any partnership news involving Gilead, Sanofi, or Incyte, could matter as well. Monitoring earnings, guidance, and analyst revisions will provide further signals.
When analyzing volatile names like this one, I find it helpful to review automated strategies alongside fundamental work. Tickeron’s AI Trading Bots offer a straightforward way to compare algorithmic approaches across different timeframes and market conditions, which can complement traditional pipeline reviews without replacing them.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The Aroon Indicator for MGNX entered a downward trend on November 04, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 216 similar instances where the Aroon Indicator formed such a pattern. In 195 of the 216 cases the stock moved lower. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MGNX as a result. In 78 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The 50-day moving average for MGNX moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for MGNX just turned positive on November 10, 2026. Looking at past instances where MGNX's MACD turned positive, the stock continued to rise in 42 of 51 cases over the following month. The odds of a continued upward trend are 82%.
Following a +3.86% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGNX advanced for three days, in 228 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
MGNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 11 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating steady price growth. MGNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.462) is normal, around the industry mean (3.596). P/E Ratio (-10.591) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (10.770) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (1.477) is also within normal values, averaging (443.347).
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the discovery and development of monoclonal antibody-based therapeutics
Industry Biotechnology